Hamano Naoto, Fukagawa Masafumi
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan.
Clin Calcium. 2017;27(4):567-572.
The oral calcimimetics, cinacalcet, is reported to be effective on secondary hyperparathyroidism resistant to classical treatment like phosphate binders or vitamin D receptor activator. The problem that gastrointestinal adverse events cause poor adherence, drug discontinuation, and insufficient dose escalation remains unsolved. The novel injectable calcimimetic, etelcalcetide, is recently developed and is expected to reduce such adverse events and improve the therapeutic effects on moderate to severe secondary hyperparathyroidism. Further studies are needed to demonstrate the potential benefits of etelcalcetide compared to cinacalcet.
口服拟钙剂西那卡塞据报道对抵抗传统治疗（如磷结合剂或维生素D受体激活剂）的继发性甲状旁腺功能亢进有效。胃肠道不良事件导致依从性差、停药和剂量增加不足的问题仍未得到解决。新型注射用拟钙剂依特卡肽最近已研发出来，预计可减少此类不良事件，并提高对中重度继发性甲状旁腺功能亢进的治疗效果。需要进一步研究以证明依特卡肽与西那卡塞相比的潜在益处。
